News
Public · Published
Immunotech Biopharm To Place Up To 123.5 Million New Shares
Immunotech Biopharm Ltd plans to place up to 123.5 million new shares at a price of not less than HK$0.300 per share, according to the supplied article.
Published:
Updated:
What happened
Immunotech Biopharm Ltd plans to place up to 123.5 million new shares at a price of not less than HK$0.300 per share, according to the supplied article.
Confirmed
Global impact / market context
Selling new shares raises cash for the company but increases the total number of shares, which can reduce each existing shareholder's share of future profit. The minimum price also signals how much the company is willing to accept per share.
Analyst inference
A share placement lets a listed company sell new stock to investors, often to fund operations. Because the number of shares grows, existing holders own a smaller percentage of the company unless they buy more shares themselves.
Analyst inference
What to watch
- The placement covers up to 123.5 million new shares, and no price below HK$0.300 per share is allowed under the stated terms. Confirmed
- Watch whether the company completes the placement and how much cash it actually raises, since the article describes a plan rather than a finished transaction. Proposed
- Track the final number of shares sold and the settled price, because both affect how much existing shareholders are diluted, meaning their ownership share is reduced. Analyst inference
Evidence
- Original source link unavailable